A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Bemcentinib (Primary) ; Dabrafenib; Pembrolizumab; Trametinib
- Indications Malignant melanoma; Skin cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Jun 2024 Status changed from active, no longer recruiting to completed.
- 24 Oct 2023 Interim Results ( database lock on August 21 2023) assessing safety and efficacy of bemcentinib in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma presented at the 48th European Society for Medical Oncology Congress
- 23 Oct 2023 According to a BerGenBio media release, results from this study were presented during the European Society of Clinical Oncologists (ESMO) Annual Meeting 2023.